These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 23642372

  • 21. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, Lotery AJ, Downes SM, Chakravarthy U, Reeves BC, IVAN Study Investigators.
    BMJ Open; 2014 Jul 29; 4(7):e005094. PubMed ID: 25079928
    [Abstract] [Full Text] [Related]

  • 22. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Tabatabaei H, Peyman GA.
    Retina; 2007 Jul 29; 27(9):1187-95. PubMed ID: 18046223
    [Abstract] [Full Text] [Related]

  • 23. Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study).
    Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Van Leeuwen R, Vingerling JR, Moll AC, Schlingemann RO.
    BMC Ophthalmol; 2015 Jul 07; 15():71. PubMed ID: 26149170
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China.
    Ming J, Zhang Y, Xu X, Zhao M, Wang Y, Chen Y, Zhang F, Wang J, Liu J, Zhao X, Han R, Hu S.
    J Comp Eff Res; 2020 Feb 07; 9(3):161-175. PubMed ID: 31904267
    [Abstract] [Full Text] [Related]

  • 25. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Monigle MC.
    Ophthalmol Retina; 2024 May 07; 8(5):431-446. PubMed ID: 37981235
    [Abstract] [Full Text] [Related]

  • 26. Practical Lessons from Protocol I for the Management of Diabetic Macular Edema.
    Mukkamala L, Bhagat N, Zarbin MA.
    Dev Ophthalmol; 2017 May 07; 60():91-108. PubMed ID: 28427069
    [Abstract] [Full Text] [Related]

  • 27. Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi.
    Vetrini D, Kiire CA, Burgess PI, Harding SP, Kayange PC, Kalua K, Msukwa G, Beare NAV, Madan J.
    PLoS One; 2018 May 07; 13(1):e0190742. PubMed ID: 29300755
    [Abstract] [Full Text] [Related]

  • 28. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.
    Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N, Faghihi Sh.
    Eur J Ophthalmol; 2008 May 07; 18(6):941-8. PubMed ID: 18988166
    [Abstract] [Full Text] [Related]

  • 29. Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up.
    Romero-Aroca P, de la Riva-Fernandez S, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N, Puig D.
    BMC Ophthalmol; 2016 Aug 04; 16():136. PubMed ID: 27491545
    [Abstract] [Full Text] [Related]

  • 30. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.
    Diabetic Retinopathy Clinical Research NetworkDepartment of Ophthalmology, Harvard Medical School, Joslin Diabetes Center, Boston, Massachusetts, USA., Writing Committee, Aiello LP, Beck RW, Bressler NM, Browning DJ, Chalam KV, Davis M, Ferris FL, Glassman AR, Maturi RK, Stockdale CR, Topping TM.
    Ophthalmology; 2011 Dec 04; 118(12):e5-14. PubMed ID: 22136692
    [Abstract] [Full Text] [Related]

  • 31. Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review.
    Maniadakis N, Konstantakopoulou E.
    Pharmacoeconomics; 2019 Aug 04; 37(8):995-1010. PubMed ID: 31012025
    [Abstract] [Full Text] [Related]

  • 32. Anti-vascular endothelial growth factor for diabetic macular oedema.
    Virgili G, Parravano M, Menchini F, Evans JR.
    Cochrane Database Syst Rev; 2014 Oct 24; (10):CD007419. PubMed ID: 25342124
    [Abstract] [Full Text] [Related]

  • 33. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
    Pochopien M, Beiderbeck A, McEwan P, Zur R, Toumi M, Aballéa S.
    BMC Health Serv Res; 2019 Jan 09; 19(1):22. PubMed ID: 30626376
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: A Markov-model.
    Pesonen M, Kankaanpää E, Vottonen P.
    Acta Ophthalmol; 2021 Nov 09; 99(7):e1146-e1153. PubMed ID: 33421332
    [Abstract] [Full Text] [Related]

  • 35. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK.
    Ophthalmology; 2010 Jun 09; 117(6):1064-1077.e35. PubMed ID: 20427088
    [Abstract] [Full Text] [Related]

  • 36. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B, Xie F.
    J Clin Oncol; 2015 Jul 10; 33(20):2296-302. PubMed ID: 26014296
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
    Holekamp N, Duff SB, Rajput Y, Garmo V.
    J Med Econ; 2020 Mar 10; 23(3):287-296. PubMed ID: 31502893
    [Abstract] [Full Text] [Related]

  • 38. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.
    Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA.
    Retina; 2012 Feb 10; 32(2):314-21. PubMed ID: 22234244
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.